Day: October 1, 2021

Dividend amount: 4.40 per shareDeclared currency: Norwegian KroneLast day including right: 4 October 2021Ex-date: 5 October 2021Record date: 6 October 2021Payment date: From 13 October 2021Date of approval: 1 October 2021 For further information, please contact:Jesper M. Hatletveit, Head of IR, Sbanken ASA, +47 959 40 045Henning Nordgulen, CFO, Sbanken ASA, +47 952 65 990 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced it will present preclinical data for its anti-VISTA (V-domain Ig suppressor of T cell activation) product candidate, SNS-101, during the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held in Washington, D.C. from November 10 – 14, 2021. These data are the first preclinical data to be presented by Sensei Bio in a scientific forum from the company’s TMAb (Tumor Microenvironment Activated biologics) platform. “Our TMAb technology has the potential to address the challenges of current immune checkpoint therapies by identifying antibodies that preferentially bind in the tumor microenvironment,...

HEIDELBERG, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that three abstracts with preclinical data of its innate cell engagers have been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held on November 10-14, 2021. Abstract details: Title: Tetravalent, bispecific innate cell engager AFM24 enhances macrophage mediated tumor cell phagocytosis Abstract ID: 880 Authors: Sheena Pinto, Susanne Wingert, Jens Pahl, Armin Beez, Sabrina Purr, Uwe Reusch, Arndt Schottelius and Joachim Koch Title: Enhanced antibody-mediated phagocytosis and antibody-mediated cell cytotoxicity using tetravalent, bispecific innate...

Media Release Copenhagen, Denmark, October 1, 2021Mini-oral presentation highlighting data from first-in-human trial evaluating investigational bispecific antibody DuoBody®-CD40×4-1BB (GEN1042) Poster presentation of clinical results from study evaluating investigational bispecific antibody DuoBody®– PD-L1×4-1BB (GEN1046) Additional poster presentations highlighting an investigational early-stage therapy in Genmab’s solid tumor product pipeline, new research and technologiesGenmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating several investigational therapies and technologies in the company’s solid tumor product pipeline will be presented at the Society for Immunotherapy of Cancer’s 36thAnnual Meeting (SITC 2021), being held in Washington, DC, and virtually, November 10-14. The presentations will include...

Bergen, 1 October 2021. The Board of Directors of Sbanken ASA has today decided to utilise the outstanding dividend authorisation for 2020 to distribute NOK 4.40 per share, corresponding to 62.8 per cent of net profit after tax. The authorisation was granted to the Board of Directors by the ordinary general meeting held on 22 April 2021. As set out in section 3.2 (Offer Price) of the Offer Document for DNB Bank ASA’s recommended voluntary cash tender offer to acquire all shares of Sbanken ASA dated 23 April 2021, DNB Bank ASA may reduce the Offer Price by an amount corresponding to the amount of such dividend distribution made by Sbanken and any acceptances of the Offer received by DNB Bank ASA shall be deemed an acceptance of the Offer as revised. Contact details, Investor RelationsJesper M. Hatletveit, Head of IR, Sbanken ASA, +47 959...

Rovio Entertainment Corporation        Stock Exchange Release             October 1, 2021 at 3 p.m. EEST Composition of the Shareholders’ Nomination Board According to the decision of the Rovio Entertainment Corporation’s 2021 Annual General Meeting, the Shareholders’ Nomination Board consists of representatives of the four largest shareholders of Rovio Entertainment Corporation, however so that at least one of the members must be appointed by an institutional investor. The following persons have been appointed to the Shareholders’ Nomination Board:• Kaj Hed, Chairman of Board of Directors, Moor Holding AB• Matthew Wilson, Deputy Member of the Board of Directors, Brilliant Problems Ltd• Esko Torsti, Head of Cross Asset Allocation, Ilmarinen Mutual Pension Insurance Company• Markus Lindqvist, Director, Sustainability, Aktia Bank Plc, legal...

LEXINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced acceptance of its abstract describing updated Phase 1 clinical trial results for AGEN1181 (Fc-enhanced anti-CTLA-4) alone and in combination with balstilimab (anti-PD-1) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, to be held November 10-14, 2021. Presentation Details: Abstract Title: AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results (NCT03860272)Abstract Number: 479Presenting Author: Dr. Anthony El-Khoueiry The full...

LONDON, Oct. 01, 2021 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, will present an oral presentation at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress being held in a virtual format from October 19-22, 2021, and two posters at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting being held in a hybrid format from November 10-14, 2021 online and in person in Washington, DC. Details of the presentations are as follows:2021 European Society for Gene and Cell Therapy (ESGCT) Congress Abstract Title: Multicentre, prospective research protocol for development of a clonal neoantigen-reactive T cell therapy pipeline across multiple tumour typesPresentation Number: OR54Session: 6c...

NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) — MiNK Therapeutics, a clinical stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced acceptance of three abstracts for presentation at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting being held between November 10-14, 2021. Presentation Details: Abstract title: Persistence and tissue distribution of AgenT-797 – a native allogeneic iNKT cell-therapy drug product (NCT04582201 and NCT04754100)Abstract number: 400Presenting author: Marco Purbhoo Abstract title: AgenT-797, a native allogeneic “off-the-shelf” iNKT cell therapy product shows anti-tumor activity in preclinical xenograft models...